Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Quallent Pharmaceuticals to Distribute Alvotech’s High Concentration Interchangeable Adalimumab in US as Private Label Medicine

Apr 30, 2024

On 30 April 2024, Alvotech announced a strategic partnership with Quallent Pharmaceuticals Health, under which a high-concentration interchangeable biosimilar to Humira® manufactured by Alvotech will be distributed under Quallent’s private-label.  This partnership aligns with Alvotech’s existing U.S. commercialisation agreement with Teva.

Alvotech and Teva’s Simlandi® received FDA approval on 24 February 2024 as the first high-concentration, citrate-free biosimilar to Humira® to be granted interchangeable status by the FDA.